Ralf Herold

机构：European Medicines Agency · ORCID：0000-0002-8148-6748

发表论文 86 篇 · 总被引 1257 次 · h-index 19

代表论文

• Recommendations on the use of item libraries for patient-reported outcome measurement in oncology trials: findings from an international, multidisciplinary working group (2023 · The Lancet Oncology · 被引 73)
• Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials-Innovative Medicines Initiative (SISAQOL-IMI): stakeholder views, objectives, and procedures (2023 · The Lancet Oncology · 被引 63)
• Health horizons: Future trends and technologies from the European Medicines Agency’s horizon scanning collaborations (2022 · Frontiers in Medicine · 被引 40)
• The Impact of COVID‐19 on the Initiation of Clinical Trials in Europe and the United States (2022 · Clinical Pharmacology & Therapeutics · 被引 34)
• EMA Recommendation for the Pediatric Indications of Plerixafor (Mozobil) to Enhance Mobilization of Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Children with Lymphoma or Malignant Solid Tumors (2020 · The Oncologist · 被引 30)
• Artificial intelligence in European medicines regulation (2022 · Nature Reviews Drug Discovery · 被引 25)